Business Context and Reporting Period
This Form 8-K Current Report was filed by Bionano Genomics, Inc. on January 24, 2019. The report addresses a material modification to the rights of security holders resulting from a recent Delaware Chancery Court decision.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and corporate governance matters rather than financial performance.
Material Changes
The primary material change concerns the enforceability of the Company's federal forum selection provision:
- Legal Precedent: On December 19, 2018, the Delaware Chancery Court issued an opinion in Sciabacucchi v. Salzberg, invalidating provisions in Delaware corporate charters that limit Securities Act of 1933 claims to federal court.
- Impact on Charter: Article VII of Bionano Genomics' Amended and Restated Certificate of Incorporation contains a similar federal forum selection provision.
- Enforcement Status: The Company does not currently intend to enforce this provision unless the Delaware Supreme Court reverses the Chancery Court's decision.
- Future Action: If the Delaware Supreme Court affirms the lower court's decision, the Company will seek stockholder approval to amend its Charter to remove the invalid provision at the next annual meeting.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operations, or standard risk factors. The primary contingency identified is the pending appeal of the Sciabacucchi decision to the Delaware Supreme Court, which will determine the future validity of the Company's forum selection clause.
Key Facts for Investor Verification
- Verify the status of the appeal in Sciabacucchi v. Salzberg before the Company's next annual meeting.
- Confirm whether the Company will propose a charter amendment to remove the federal forum selection provision if the Delaware Supreme Court affirms the Chancery Court's ruling.
- Note that this filing does not disclose any changes to the Company's financial position or operational strategy.